Clinical Trial Update: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial of Globo H-KLH (OPT-822) active immunotherapy in metastatic breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• OPT-822 (Globo H-KLH)

Snippet

Sponsor: OBI Pharma, Inc | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED